In addition to the Martin Shkreli buys on KaloBios Pharma (NASDAQ: KBIO) disclosed after the close, Anthion Partners II disclosed it bought 713,726 shares on 11/16 at $1.26-$1.76. Shares are up 700% after-hours.

Insider Trades Momentum Movers Short Sales Trader Talk

Macrocure (MCUR) Ramps HigherNovember 20, 2015 10:47 AM Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall StreetNovember 19, 2015 1:36 PM Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Anthion Partners II LLCNovember 18, 2015 5:34 PM Market Wrap: Fed Hints at Dec. Hike; China Trims Treasury Holdings; Housing Starts Lags in Oct.; Apple Gains on Goldman CallNovember 18, 2015 5:26 PM Celladon (CLDN) Moves Higher in Concert with KaloBios Pharma (KBIO) Following Shkreli StakeNovember 18, 2015 5:24 PM With Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4November 18, 2015 4:57 PM KaloBios Pharma (KBIO) Pops on Shkreli Insider BuyNovember 18, 2015 4:25 PM Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Shkreli MartinNovember 18, 2015 4:10 PM